Olanzapine is an effective antipsychotic medication, but the associated weight gain is the number one cause of discontinuation, explained Adam Simmons, director of clinical program management, Alkermes, during an interview at the 175th Annual Meeting of the American Psychiatric Association in San Francisco, California. An investigational drug, ALKS 3831, aims to mitigate the weight gain associated with olanzapine.
Olanzapine is an effective antipsychotic medication, but the associated weight gain is the number one cause of discontinuation, explained Adam Simmons, director of clinical program management, Alkermes, during an interview at the 175th Annual Meeting of the American Psychiatric Association in San Francisco, California. An investigational drug, ALKS 3831, aims to mitigate the weight gain associated with olanzapine.
Transcript
Where does weight gain rank among the causes of nonadherence to olanzapine?
In terms of nonadherence, specifically related to olanzapine, there was a study that was done back when a lot of these antipsychotics first came to market called the CATIE [Clinical Antipsychotic Trials of Intervention Effectiveness] Study, and what they did in that study is they looked at all-cause discontinuation, another measure of antipsychotic adherence, and whether or not people stay on these medications. And olanzapine was the antipsychotic medication that people stayed on the longest in comparison to other second-generation antipsychotics as well as some of the first-generation antipsychotics. So it’s already established as something that people can stay on, but if you look into that data a little bit further and you look at the reasons that people discontinue olanzapine, the number one reason is because weight gain and metabolic side effects. So the thought here is that if we take a drug that’s already established and has very good efficacy and that has very good adherence and people stay on anyway, and we can remove the one reason that people typically choose to discontinue it, that people would be able to stay on the medication longer.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More